POLM

DNA-directed DNA/RNA polymerase mu

3,344 patent compounds predicted against POLM, 2,022 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL6366589	0.71	2/20
SCHEMBL7911252	0.67	2/20
SCHEMBL8176587	0.64	2/20
SCHEMBL3054875	0.63	2/20
SCHEMBL10394363	0.63	2/20
SCHEMBL10395154	0.63	2/20
SCHEMBL3179332	0.62	2/20
SCHEMBL10571781	0.62	2/20
SCHEMBL10499098	0.61	2/20
SCHEMBL10499112	0.61	2/20
SCHEMBL5167656	0.60	2/20
SCHEMBL10407328	0.60	2/20
SCHEMBL454163	0.60	2/20
SCHEMBL7710665	0.60	2/20
SCHEMBL1287104	0.59	2/20
SCHEMBL1257476	0.59	2/20
SCHEMBL9179143	0.59	2/20
SCHEMBL8389556	0.58	2/20
SCHEMBL3420357	0.57	2/20
SCHEMBL4083649	0.57	2/20

Germline variants in POLM on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full POLM gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to POLM by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection	PHASE3	UNKNOWN
Intracameral Antibiotic Safety Study	PHASE3	SUSPENDED
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)	PHASE3	COMPLETED
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	PHASE2	UNKNOWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs	PHASE2	COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
Endometrial Receptivity in Patients With Recurrent Implantation Failure as a Preparatory Step for PET	PHASE1/PHASE2	UNKNOWN
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia	PHASE1	COMPLETED
An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer	nan	NOT_YET_RECRUITING
Choroid Plexus Dysfunction in Neurological Diseases	nan	RECRUITING
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED
Cohort of Tumors With POLE/D1 Mutation	nan	RECRUITING
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.	nan	UNKNOWN
Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation	nan	UNKNOWN
Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome)	nan	COMPLETED
Primary and Secondary Drug Resistance Mutations (DRMs) in HIV As a Risk Factor of Failure of ART, Including Two Drugs Based Regimens.	nan	NOT_YET_RECRUITING
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a POLM binder may also engage these)

Protein	Name	Similarity
Q9JIW4	—	0.994	Q9JIW4 →
Q8BNV1	—	0.966	Q8BNV1 →
Q8N9H8	—	0.963	Q8N9H8 →
Q92089	—	0.960	Q92089 →
Q6AYG0	—	0.956	Q6AYG0 →
Q9DD16	—	0.955	Q9DD16 →
Q2TBI8	—	0.955	Q2TBI8 →
Q6P9U1	—	0.954	Q6P9U1 →
Q8IZ69	—	0.954	Q8IZ69 →
MRM1	rRNA methyltransferase 1, mitochondrial	0.953	landscape →
Q501J2	—	0.952	Q501J2 →
Q5E9V4	—	0.951	Q5E9V4 →
Q32M88	—	0.951	Q32M88 →
Q8BZG5	—	0.951	Q8BZG5 →
Q60I27	—	0.950	Q60I27 →
Q59I47	—	0.950	Q59I47 →
Q8TDF6	—	0.950	Q8TDF6 →
Q9BQD7	—	0.950	Q9BQD7 →
A6QP75	—	0.950	A6QP75 →
PDCD2L	Programmed cell death protein 2-like	0.950	landscape →
Q6IMX7	—	0.949	Q6IMX7 →
PKN3	Serine/threonine-protein kinase N3	0.949	landscape →
Q6XQN1	—	0.949	Q6XQN1 →
HDAC10	Polyamine deacetylase HDAC10	0.948	landscape →
Q99J25	—	0.948	Q99J25 →
P46718	—	0.948	P46718 →
PKN1	Serine/threonine-protein kinase N1	0.948	landscape →
P70295	—	0.948	P70295 →
Q17QS4	—	0.948	Q17QS4 →
PPM1F	Protein phosphatase 1F	0.947	landscape →